The Week Ahead In Biotech: Conferences, Clinical Trials

The new year kick started with a bumper deal in the pharma space, with Bristol-Myers Squibb Co (NYSE: BMY) agreeing to buy Celgene Corporation (NASDAQ: CELG).

Can the deal infuse some momentum into the space following a down year? Here are some key catalysts of the upcoming week that could provide an answer.